阿美替尼治疗晚期非小细胞肺癌研究进展

doi:10.19803/j.1672-8629.20240491

摘要/Abstract

摘要： 目的研究阿美替尼作为第三代表皮生长因子受体酪氨酸激酶抑制剂（Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors, EGFR-TKIs）对表皮生长因子受体（Epidermal Growth Factor Receptor, EGFR）突变晚期非小细胞肺癌（Non-Small Cell Lung Carcinoma, NSCLC）患者的临床疗效。方法从阿美替尼治疗EGFR经典突变的晚期NSCLC临床疗效、阿美替尼治疗T790M耐药突变的晚期NSCLC临床疗效、阿美替尼治疗罕见的EGFR突变晚期NSCLC的临床疗效及阿美替尼联合治疗延缓耐药性发生的临床研究进展进行论述。结果在真实世界研究中,阿美替尼对于EGFR经典突变的晚期NSCLC患者,其中位无进展生存期（Median Progression-Free Survival, mPFS）延长至20个月,对于T790M耐药突变的晚期NSCLC患者,其mPFS延长至15个月,对罕见突变的晚期NSCLC患者也有良好疗效,阿美替尼联合治疗方案能够有效减缓耐药性的发生。结论阿美替尼对晚期NSCLC患者临床疗效较好,能有效提高患者的生存期及改善患者预后。

关键词: 阿美替尼, 非小细胞肺癌, 表皮生长因子受体酪氨酸激酶抑制剂, 表皮生长因子受体, 联合治疗, 罕见突变, 临床疗效, 不良反应

Abstract: Objective To investigate the clinical efficacy of aumonertinib as the third representative epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) in patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). Methods The clinical efficacy of aumonertinib against advanced NSCLC with classical EGFR mutation, advanced NSCLC with T790M drug-resistant mutation, and advanced NSCLC with rare EGFR mutation as well as the research progress in combined treatment with aumonertinib to delay the occurrence of drug resistance were reviewed. Results In real-world studies, aumonertinib extended the median progression-free survival (mPFS) to 20 months in NSCLC patients with classical EGFR mutations and to 15 months in NSCLC patients with T790M resistance mutations. Aumonertinib also showed good efficacy in NSCLC patients with rare mutations. The combination therapy with aumonertinib could effectively slow down the occurrence of drug resistance. Conclusion Aumonertinib has a marked clinical effect on patients with advanced NSCLC, which can effectively improve the survival time and prognosis of patients.

Key words: Aumolertinib, Non-small Cell Lung Cancer, Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs), Epidermal Growth Factor Receptor(EGFR), Combination Therapy, Rare Mutations, Clinical Effects, Adverse Reaction

中图分类号:

杨升锡, 许均通, 屠文莲. 阿美替尼治疗晚期非小细胞肺癌研究进展[J]. 中国药物警戒, 2025, 22(2): 235-240.

YANG Shengxi, XU Juntong, TU Wenlian. Research Progress in the Treatment of Advanced Non-Small Cell Lung Cancer with Aumonertinib[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 235-240.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20240491

https://zgywjj.magtechjournal.com/CN/Y2025/V22/I2/235

参考文献

[1] SUNG H, FERLAY J, SIEGEL RL, et al.Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: a Cancer Journal for Clinicians, 2021, 71(3): 209-249.
[2] UGO T, GERMANA C, ELVIRA P.Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells[J]. Cancers, 2018, 10(8): 248.
[3] HARRISON PT, VYSE S, HUANG PH.Rare Epidermal Growth Factor Receptor (EGFR) Mutations in Non-Small Cell Lung Cancer-Sciencedirect[J]. Seminars in Cancer Biology, 2020, 61: 167-179.
[4] TAN CS, KUMARAKULASINGHE NB, HUANG YQ, et al.Third Generation EGFR Tkis: Current Data and Future Directions[J]. Molecular Cancer, 2018, 17(1): 1~14.
[5] ZHANG C, SHI C, XIE JY, et al.Research Progress In Aumolertinib in The Treatment of Non-Small-Cell Lung Cancer[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2022, 42(15): 1613-1618.
[6] DING J, DING X, ZENG J, et al.Furmonertinib for Egfr-Mutant Advanced Non-Small Cell Lung Cancer: a Glittering Diamond in the Rough of EGFR-TKI[J]. Frontiers in Pharmacology, 2024, 15: 1357913.
[7] CHEN W, MIAO J, WANG Y, et al.Comparison of the Efficacy and Safety of First-Line Treatments for of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Asian Populations: a Systematic Review and Network Meta-Analysis[J]. Front Pharmacol, 2023, 14: 1212313.
[8] LU S, DONG X, JIAN H, et al.Aeneas: a Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastaticnon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or l858r Mutations[J]. Journal of Clinical Oncology, 2022, 40(27): 3162-3171.
[9] SHI Y, CHEN G, WANG X, et al.Furmonertinib(ast2818) Versus Gefitinib as First-Line Therapy for Chinese Patients With Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small-Cell Lung Cancer (furlong): a Multicentre, Double-Blind, Randomised Phase 3 Study[J]. The Lancet Respiratory Medicine, 2022, 10(11): 1019-1028.
[10] SORIA JC, OHE Y, VANSTEENKISTE J, et al.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. New England journal of medicine, 2018, 378(2): 113-125.
[11] WU FY, CHEN WD, XIA PP, et al.Clinical Observation of Icotinib Versus Gefitinib in the Treatment of EGFR Mutant Advanced Non-Small-Cell Lung Cancer[J]. Chinese Pharmacy(中国药房), 2023, 34(10): 1228-1232.
[12] ZHANG X, ZHANG M, DU X, et al.Clinical Efficacy and Safety Analysis of Aumolertinib in Real-World Treatment of EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. Frontiers in Pharmacology, 2024, 15: 1331138.
[13] ZHANG D, LIU X, SHEN F, et al.Osimertinib Versus CompaRator First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-Line Treatment in Patients with Advanced EGFR-Mutated Non-small Cell Lung Cancer: a Chinese, Multicenter, Real-World Cohort Study[J]. Translational Lung Cancer Research, 2023, 12(11): 2229.
[14] YAN N, GUO S, HUANG S, et al.The Efficacy of Furmonertinib in Untreated Advanced Nsclc Patients with Sensitive EGFR Mutations in a Real-World Setting: a Single Institutional Experience[J]. Frontiers in Oncology, 2024, 14: 1331128.
[15] ZHANG K, YANG KL, WANG HM.Comparison of Short-Term and Long-Term Effects of Almonertinib and Furmonertinib on Egfr Mutations in Advanced nsclc Patients[J]. Journal of Rare and Uncommon Diseases(罕少疾病杂志), 2024, 31(7): 27-29.
[16] MOK TS, WU YL, AHN MJ, et al.Osimertinib or Platinum-Pemetrexed in EGFR t790m-Positive Lung cancer[J]. New England Journal of Medicine, 2017, 376(7): 629-640.
[17] TALELE TT.The”Cyclopropyl Fragment”is a Versatile Player That Frequently Appears in Preclinical/Clinical Drug Molecules[J]. Journal of Medicinal Chemistry, 2016 , 59(19): 8712.
[18] LU S, WANG Q, ZHANG G, et al.Efficacy of Aumolertinib (hs-10296) in Patients with Advanced EGFR t790m+ Nsclc: Updated Post-National Medical Products Administration Approval Results From the Apollo Registrational Trial-Tciencedirect[J]. Journal of Thoracic Oncology, 2022, 17( 3): 411-422.
[19] HIRASHSHIMA T, SATOUCHI M, HIDA T, et al.Osimertinib for Japanese Patients with t790m-Positive Advanced Non-Small-Cell Lung Cancer: A pooled Subgroup Analysis[J]. Cancer Science, 2019, 110(9): 2884-2893.
[20] MENG XY, ZHANG L, XUE SP.Efficacy of Sequential Osimertinib or Aumolertinib in the Treatment of Advanced Nsclc Patients With EGFR Mutation After Drug Resistance to the First and Second Generation EGFR-TKI[J]. Evaluation and Analysis of Drug-Use in Hospitals of China(中国医院用药评价与分析), 2023, 23(9): 1079-1081, 1085.
[21] KIM H, AHN BC, LEE J, et al.Lazertinib in Pretreated EGFR t790m-Mutated Advanced Non-Small Cell Lung Cancer: a Real-World Multicenter Study[J]. Lung Cancer, 2023, 180: 107213.
[22] SHI Y, HU X, ZHANG S, et al.Efficacy, Safety, and Genetic Analysis of Furmonertinib (ast2818) in Patients With EGFR t790m Mutated Non-Small-Cell Lung Cancer: a Phase 2b, Multicentre, Single-Arm, Open-Label Study[J]. The Lancet Respiratory Medicine, 2021, 9(8): 829-839.
[23] SHI C, ZHANG C, FU Z, et al.Antitumor Activity of Aumolertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations[J]. Acta Pharmaceutica Sinica B, 2023, 13(6): 2613-2627.
[24] LI L.Two Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastasis Harboring Epidermal Growth Factor Receptor (EGFR) G719x and l861q Mutations Benefited From Aumolertinib: two Cases Report and Review of the Literature[J]. Heliyon, 2022, 8(9): 10407.
[25] WEI X, ZHANG G, LIU Q, et al. Almonertinib and Alflutinib Show Novel Inhibition on Rare EGFR S768i Mutant Cells[J/OL]. Clinical and Translational Oncology, (2024-05-30) [2024-05-31]. https://doi.org/10.1007/s12094-024-03494-5.
[26] LI L, HUANG S, QIN L, et al.Successful Treatment of Lung Adenocarcinoma Complicated with a Rare Compound EGFR Mutation l833v/h835l Using Aumolertinib: A Case Report and Literature Review[J]. Frontiers in Pharmacology, 2023, 14(8): 1257592.
[27] DENG Y, YANG C, LIU W, et al.Aumolertinib-Based Comprehensive Treatment for an Uncommon Site of EGFR Exon 20 Insertion Mutations with Multiple Metastases Non-Small Cell Lung Cancer: a Case Report[J]. Anti-Cancer Drugs, 2022, 33(4): 406-412.
[28] QI R, FU X, YU Y, et al.Efficacy and Safety of Re-Challenging 160 mg Furmonertinib for Advanced Nsclc After Resistance to Third-Generation EGFR-TKIS Targeted Agents: A Real-World Study[J]. Lung Cancer, 2023, 184: 107346.
[29] ARAKI T, KANDA S, HORINOUCHI H, et al.Current Treatment Strategies for EGFR-Mutated Non-Small Cell Lung Cancer: from First Line to Beyond Osimertinib Resistance[J]. Japanese Journal of Clinical Oncology, 2023, 53(7): 547-561.
[30] HOSOMI Y, MORITA S, SUGAWARA S, et al.Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor: nej009 Study[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020, 38(2): 115-123.
[31] CHENG Y, MURAKAMI H, YANG PC, et al.Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutations[J]. Journal of Clinical Oncology, 2016, 34(27): 3258-3266.
[32] PLANCHARD D, FENG PH, KARASEVA N, et al.Osimertinib Plus Platinum-Pemetrexed in Newly Diagnosed Epidermal Growth Factor Receptor Mutation-Positive Advanced/Metastatic Non-Small-Cell Lung Cancer: Safety Run-in Results From the Flaura2 Study[J]. ESMO Open, 2021, 6(5): 100271.
[33] MELINCOVICI CS, BOCA AB, UMAN S, et al.Vascular Endothelial Growth Factor (vegf)-Key Factor in Normal and Pathological Angiogenesis[J]. Romanian Journal of Morphology and Embryology, 2018, 59(2): 455-467.
[34] ANNA M, AGNESE M, GUIDO C, et al.Angiogenesis Inhibitors in nsclc[J]. International Journal of Molecular Sciences, 2017, 18(10): 2021.
[35] LE X, NILSSON M, GOLDMAN J, et al.Dual egfr-vegf Pathway Inhibition: a Promising Strategy for Patients With Egfr-Mutant Nsclc[J]. Journal of Thoracic Oncology, 2021, 16(2): 205-215.
[36] ZHANG Y, ZENG L, ZHANG X, et al.Clinical and Molecular Feature-Based Nomogram Model for Predicting Benefit From Bevacizumab Combined with First-Generation Egfr-Tyrosine Kinase Inhibitor (tki) in Egfr-Mutant Advanced Nsclc[J]. BMC Medicine, 2021, 245(19): 1-11
[37] YANG GX, CHENG YT, LIU LL, et al.Clinical Trial of Ametinib Tablets Combined With Bevacizumab Injection in the Treatment of Advanced Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation[J].The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2023, 39(11): 1528-1532.
[38] NIEDERST MJ, HU H, MULVEY HE, et al.The Allelic Context of the c797s Mutation Acquired Upon Treatment With Third-Generation Egfr inhibitors Impacts Sensitivity to Subsequent Treatment Strategies[J]. Clinical Cancer Research, 2015, 21(17): 3924-3933.
[39] WANG Z, YANG JJ, HUANG J, et al.Lung Adenocarcinoma Harboring Egfr t790m and in Trans c797s Responds to Combination Therapy of First-and Third-Generation Egfr Tkis and Shifts Allelic Configuration at Resistance[J]. Journal of Thoracic Oncology, 2017, 12(11): 1723-1727.
[40] RANGACHARI D, TO C, SHPILSKY JE, et al.Egfr-Mutated Lung Cancers Resistant to Osimertinib Through Egfr c797s Respond to First-Generation Reversible Egfr Inhibitors but Eventually Acquire Egfr t790m/c797s in Preclinical Models and Clinical Samples[J]. Journal of Thoracic Oncology, 2019, 14(11): 1995-2002.
[41] ROTOW JK, COSTA DB, PAWELETZ CP, et al. Concurrent Osimertinib Plus Gefitinib for First-line Treatment of Egfr-Mutated Non-Small Cell Lung Cancer (nsclc)[J]. Journal of Clinical Oncology, 2020, 3 8(suppl 15): 9507-9507.
[42] MANCINI M, GAL H, GABORIT N, et al.An Oligoclonal Antibody Durably Overcomes Resistance of Lung Cancer to Third-Generation Egfr inhibitors[J]. EMBO Molecular Medicine, 2018, 10(2): 294-308.
[43] CHIBORI K, INASE N, ARAKI M, et al.Brigatinib Combined With Anti-Egfr Antibody Overcomes Osimertinib Resistance in Egfr-Mutated Non-Small-Cell Lung Cancer[J]. Nature Communications, 2017, 8(1): 14768.